Drug Profile
Nebicapone
Alternative Names: BIA-3202Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bial
- Developer BIAL
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 17 May 2016 Discontinued - Phase-I for Parkinson's disease (Combination therapy, In volunteers) in Portugal (PO) (NCT02778594)
- 17 May 2016 Discontinued - Phase-I for Parkinson's disease (In volunteers) in Switzerland (PO)
- 17 May 2016 Discontinued - Phase-I for Parkinson's disease in Portugal (unspecified route)